TBC-256

N/A

Report date: 2025/02/01 20:00:06
NME

Base Information

Drug NameTBC-256
Drug Alias NameFGF antagonists (Texas Biotech)growth factor antagonists (Texas Biotech)TBC-256
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionFibroblast growth factor receptors antagonists
TargetsFibroblast growth factor receptors
Therapy Area/IndicationsCardiovascular DiseasesNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusDiscontinued (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesEncysive Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesArctic Therapeutics InternationalEncysive Pharmaceuticals IncSanofi-Synthelabo
Active IndicationsN/A
Inactive IndicationsCardiovascular DiseasesNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A